These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8584651)

  • 21. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release.
    Dluzen DE; McDermott JL; Liu B
    J Neurochem; 1996 Feb; 66(2):658-66. PubMed ID: 8592137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia.
    Chiueh CC; Wu RM; Mohanakumar KP; Sternberger LM; Krishna G; Obata T; Murphy DL
    Ann N Y Acad Sci; 1994 Nov; 738():25-36. PubMed ID: 7832434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of deprenyl and MPTP on catecholamines and activity in BALB/c mice.
    Chia LG; Liu SP; Lee EH
    Neuroreport; 1992 Sep; 3(9):777-80. PubMed ID: 1421136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
    Dluzen D; Jain R; Liu B
    J Neurochem; 1994 Jan; 62(1):94-101. PubMed ID: 8263548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
    Adeyemo OM; Youdim MB; Markey SP; Markey CJ; Pollard HB
    Eur J Pharmacol; 1993 Aug; 240(2-3):185-93. PubMed ID: 8243537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse.
    Thiffault C; Lamarre-Théroux L; Quirion R; Poirier J
    Brain Res Mol Brain Res; 1997 Mar; 44(2):238-44. PubMed ID: 9073165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
    Schneider JS; DiStefano L
    Neuroreport; 1993 Nov; 5(2):103-4. PubMed ID: 8110995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
    Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
    Przedborski S; Jackson-Lewis V; Yokoyama R; Shibata T; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 1996 May; 93(10):4565-71. PubMed ID: 8643444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
    Pérez V; Morón J; Pastó M; Unzeta M
    Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice.
    Dluzen DE; McDermott JL; Liu B
    Neurotoxicol Teratol; 1996; 18(5):603-6. PubMed ID: 8888025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice.
    Ookubo M; Yokoyama H; Takagi S; Kato H; Araki T
    Mol Cell Endocrinol; 2008 Dec; 296(1-2):87-93. PubMed ID: 18755240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
    Saitoh T
    J Neurol Sci; 1988 Feb; 83(2-3):161-6. PubMed ID: 3258627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
    Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
    Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
    Boireau A; Bordier F; Dubédat P; Pény C; Impérato A
    Neurosci Lett; 1997 Oct; 234(2-3):123-6. PubMed ID: 9364513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Lau YS; Fung YK; Trobough KL; Cashman JR; Wilson JA
    Neurotoxicology; 1991; 12(2):189-99. PubMed ID: 1956580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment.
    West BD; Shughrue PJ; Vanko AE; Ransom RW; Kinney GG
    Pharmacol Biochem Behav; 2006 May; 84(1):158-61. PubMed ID: 16757017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.